Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa

Fig. 3

Forest plots of the effects of PAG versus AG in terms of PFS and OS by C3M/PRO-C3 ratio subgroups in Stage 1 and Stage 2 of HALO 109-202. In Stage 1, C3M/PRO-C3 ratio subgroups for PFS analysis were defined by median cut-off and ROC cut-off. In Stage 2, C3M/PRO-C3 ratio subgroups for PFS and OS analyses were defined by median cut-off derived from Stage 1 and ROC cut-off derived from Stage 1. Both median and ROC cut-offs for C3M/PRO-C3 ratio predicted a statistically significant benefit (P < .05) in PFS (Stage 1 and Stage 2) and OS (Stage 2) for PAG vs AG. ROC cut-off point from Stage 1 for the low biomarker subgroup was < 0.702. ROC cut-off point from Stage 1 for the high biomarker subgroup was ≥ 0.702

Back to article page